Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 11/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696500 | 0.82 | ALDH1A1 (0.55) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL6765648 | 0.80 | AR (0.44) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL24495415 | 0.79 | ALDH1A1 (0.49) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL3272602 | 0.79 | ALDH1A1 (0.49) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL10540003 | 0.78 | ALDH1A1 (0.52) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL23880593 | 0.78 | ALDH1A1 (0.52) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL7365630 | 0.77 | ALDH1A1 (0.50) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL5750458 | 0.77 | ALDH1A1 (0.50) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL6954237 | 0.77 | ALDH1A1 (0.50) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 | |
| SCHEMBL8039491 | 0.77 | ALDH1A1 (0.59) | ALDH1A1IMPDH2IMPDH1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009126785-A | METHOD FOR PRODUCING 2-IODO-3,4-DIMETHOXYBENZONITRILE | MITSUBISHI GAS CHEM CO INC | 2009-06-11 | — | — | JP | disclosed |
| JP-2009126784-A | METHOD FOR PRODUCING 2-IODO-3,4-DIMETHOXYBENZONITRILE | MITSUBISHI GAS CHEM CO INC | 2009-06-11 | — | — | JP | disclosed |
| CN-1191249-C | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2005-03-02 | — | — | CN | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| CN-1403453-A | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2003-03-19 | — | — | CN | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
| CN-1205693-A | Quinoline and quinazoline compounds useful in therapy | PFIZER RES & DEV (IE) | 1999-01-20 | — | — | CN | disclosed |
| EP-0877734-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997023462-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | ALDH1A1 498/4885IMPDH2 1684/4885IMPDH1 1000/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | ALDH1A1 514/4885IMPDH2 1555/4885IMPDH1 909/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | ALDH1A1 420/4885IMPDH2 1502/4885IMPDH1 900/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | ALDH1A1 557/4885IMPDH2 1599/4885IMPDH1 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.